Article

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML

2017-06-14

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bbcd43d6-7f0f-5720-bbca-3f068f79071e
DOI: 10.1101/124263

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLDOI 10.1101/124263Read

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity Read

Differentiation therapy of myeloid leukemia: four decades of developmentSemantic proximity Read

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaSemantic proximity Read

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read

DecitabineSemantic proximity Read

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic ParadigmsSemantic proximity Read

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity Read

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaSemantic proximity Read